The Prescient Therapeutics Ltd (ASX: PTX) share price is plunging during late afternoon trade on Wednesday.
This follows the companyâs latest announcement regarding the launch of a share purchase plan (SPP).
At the time of writing, shares in the clinical stage oncology company are fetching at 18.5 cents each, down 11.90%.
What are the SPP details?
A catalyst for the steep dive in the Prescient share price today is investor fears of an impending share dilution.
According to its release, Prescient advised it is seeking to raise $8 million via an SPP from retail investors.
Under the SPP, eligible shareholders can apply to buy a parcel of Prescient shares for 17.5 cents each.
This represents a 14.6% discount to the volume weighted average price (VWAP) over the last five trading days, and a 16.7% discount to the last closing price on 23 August 2022.
Eligible shareholders can apply for a minimum application amount of $5,000 with a maximum application amount of $30,000.
The closing date for the SPP will be 28 September. The new shares will be issued on 5 October, with trading available the following day.
Prescient will use the funds to progress the ongoing clinical development of its targeted therapies PTX-100 and PTX-200.
In addition, the company is aiming to advance its innovative cell therapies towards and into first-in-human clinical studies.
Prescient CEO and managing director, Steven Yatomi-Clarke commented:
The last couple of years in particular have been a period of incredible growth and progress for Prescient, and the company is seeking to maintain this momentum and its position at the forefront of oncology innovationâ¦
Prescient share price snapshot
Since the beginning of the calendar year, Prescient shares have travelled lower to post a loss of 20%.
However, when looking at the year-to-date, the companyâs shares are up 3%.
Based on todayâs price, Prescient commands a market capitalisation of around $114.58 million with approximately 654.73 million shares on issue.
The post Why is the Prescient share price diving 12% on Wednesday? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Prescient Therapeutics Ltd right now?
Before you consider Prescient Therapeutics Ltd, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Prescient Therapeutics Ltd wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of August 4 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- What’s been happening with the Nuix share price of late?
- ASX tech share Xref rallies on 834% profit boost
- Guess which ASX lithium share is rocketing 20% on positive drill results
- Which 3 ASX mining shares are soaring more than 15% today?
- 2 exciting small cap ASX shares that analysts say have huge potential
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/XtLPFqC
Leave a Reply